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CLINICAL INVESTIGATIONS
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Abstract
Background: Previous studies examining the use of direct oral anticoagulants
(DOACs) in atrial fibrillation (AF) have largely focused on patients newly initiating
therapy. Little is known about the prevalence/patterns of switching to DOACs among
AF patients initially treated with warfarin.
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Hypothesis: To examine patterns of anticoagulation among patients chronically managed with warfarin upon the availability of DOACs and identify patient/practice-level
factors associated with switching from chronic warfarin therapy to a DOAC.
Methods: Prospective cohort study of AF patients in the NCDR PINNACLE registry
prescribed warfarin between May 1, 2008 and May 1, 2015. Patients were followed
at least 1 year (median length of follow-up 375 days, IQR 154-375) through May
1, 2016 and stratified as follows: continued warfarin, switched to DOAC, or

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; ACC/AHA/HRS, American College of Cardiology/American Heart Association/Heart Rhythm Society; NCDR, National
Cardiovascular Disease RegistryPINNACLEPractice Innovation and Clinical Excellence; CKD, chronic kidney disease; GFR, glomerular filtration rate.
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discontinued anticoagulation. To identify significant predictors of switching, a threelevel multivariable hierarchical regression was developed.
Results: Among 383 008 AF patients initially prescribed warfarin, 16.3% (n = 62 620)
switched to DOACs, 68.8% (n = 263 609) continued warfarin, and 14.8%
(n = 56 779) discontinued anticoagulation. Among those switched, 37.6% received
dabigatran, 37.0% rivaroxaban, 24.4% apixaban, and 1.0% edoxaban. Switched
patients were more likely to be younger, women, white, and have private insurance
(all P < .001). Switching was less likely with increased stroke risk (OR, 0.92; 95%CI,
0.91-0.93 per 1-point increase CHA2DS2-VASc), but more likely with increased
bleeding risk (OR, 1.12; 95%CI, 1.10-1.13 per 1-point increase HAS-BLED). There
was substantial variation at the practice-level (MOR, 2.33; 95%CI, 2.12-2.58) and
among providers within the same practice (MOR, 1.46; 95%CI, 1.43-1.49).
Conclusions: Among AF patients treated with warfarin between October 1, 2010
and May 1, 2016, one in six were switched to DOACs, with differences across
sociodemographic/clinical characteristics and substantial practice-level variation. In
the context of current guidelines which favor DOACs over warfarin, these findings
help benchmark performance and identify areas of improvement.
KEYWORDS

atrial fibrillation, direct oral anticoagulants, patterns of care, practice patterns, warfarin
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I N T RO DU CT I O N

disparities in care based on sociodemographic and clinical factors. We
hypothesized that there would be significant disparities in switching

Anticoagulation significantly decreases stroke risk in atrial fibrillation

patterns and substantial patient/practice-level variations.

(AF).1 Although warfarin was previously the standard treatment for
stroke prevention in AF, direct oral anticoagulant (DOAC) medications
have been approved for nonvalvular AF since 2010. Compared to

2

METHODS

|

warfarin, these medications have been shown to provide more consistent anticoagulant effect, substantially reduce the risk of intracranial

2.1

|

Data source

hemorrhage, have fewer interactions with other drugs/food, and do
not require international normalized ratio (INR) monitoring.2,3 As a

The NCDR PINNACLE registry is a prospective outpatient quality

result, the 2019 update to the American College of Cardiology (ACC)/

improvement registry that was created by the ACC in 2008.10 In this

American Heart Association (AHA)/Heart Rhythm Society (HRS) AF

registry, both academic and private practices collect longitudinal data

guidelines favor the use of DOACs over warfarin for stroke preven-

pertaining to the care of patients with AF, coronary artery disease,

4

tion in nonvalvular AF with a class 1A recommendation.

hypertension, and heart failure. This includes demographics, medical

Previous studies from the National Cardiovascular Disease

comorbidities, medications, and practice/provider data. These data

Registry's (NCDR) Practice Innovation and Clinical Excellence

are collected from the patients' charts using a standardized collection

(PINNACLE) registry have examined patterns of DOAC use in AF, and

tool to obtain and transmit data. De-identified data was extracted

have noted disparities in DOAC use based on sex, race, and insurance

from an electronic medical record under a quality improvement model,

status.5-9 However, these analyses have focused exclusively on

with approval from an institutional review board and informed con-

patients newly initiating anticoagulation for AF. There is limited data

sent waived. Rigorous data definitions and periodic data quality audits

evaluating how commonly patients on warfarin are switched to

are conducted to maintain NCDR data quality assurance.11 Analysis of

7

DOACs and why they are switched. The NCDR PINNACLE registry

the data was performed at the Baim Institute for Clinical Research.

longitudinally follows patients with AF, providing insight into patterns
of switching oral anticoagulant therapy and identifying patient and
practice-level factors associated with switching.10

2.2

|

Study population

Accordingly, we sought to examine patterns of anticoagulation
among patients with AF treated with warfarin, determine predictors

The study cohort included all patients with nonvalvular AF, in the PIN-

of switching from warfarin to DOACs, and identify potential

NACLE dataset with at least one warfarin prescription between
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January 1, 2008 and May 1, 2015. Patients were followed longitudi-

distribution was examined, additional practice-level analyses were

nally in PINNACLE and stratified based upon their anticoagulation

conducted by stratifying practices into tertiles based on the propor-

between October 1, 2010 and May 1, 2016 as follows: (a) continued

tion of patients who were switched to a DOAC (tertiles were arranged

warfarin, (b) switched to a DOAC, and (c) discontinued anti-

from lowest switching rates to highest).

coagulation. Patients were substratified by the date of index visit

To measure practice variation, the median odds ratio (MOR)

(2010-2011, 2012-2013, and 2014-2016) and time after index visit

was used. The MOR is able to provide cluster-level variance when a

(30 days, 90 days, 180 days, 365 days, and more than 365 days).

multilevel regression analysis is performed and can assess variation

Patients were considered to have switched if they had a DOAC

in a mixed effects model. An MOR >1.2 suggests clinically signifi-

recorded on two consecutive visits in the registry. Patients were

cant variation in the outcome among a unit after adjustment for

excluded if they were younger than 18 years of age, or did not have a

fixed effects. In this analysis, an MOR >1.2 suggests clinically signifi-

second encounter after the initiation of warfarin. Additionally,

cant variation among practices in switching from warfarin to a

patients were excluded if they had a history of cardiac valve surgery

DOAC.12

(valve replacement/valvular AF) or systemic embolism recorded in the
registry, in order to analyze patients who were potentially eligible to

3

switch.

3.1
2.3
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RE SU LT S

|

Study cohort

|

Statistical methods
There were 485 986 patients in the PINNACLE registry with AF on

The primary outcome of this study was the proportion of patients

warfarin between May 1, 2008 and May 1, 2015. Of these patients,

with AF treated with warfarin that were switched to a DOAC and the

102 978 were excluded from the analysis due to cardiac valve sur-

proportion switched to each specific agent. We calculated the propor-

gery, systemic embolism, age less than 18, missing sex, or missing fol-

tion of patients with AF treated with warfarin that were switched to a

low up encounters (Figure 1). This resulted in 383 008 patients

DOAC, and then calculated the proportion switched to each specific

included in the analysis with at least one prescription for warfarin for

agent (dabigatran, rivaroxaban, apixaban, and edoxaban). Among the

AF between May 1, 2008 and May 1, 2015, who were eligible to be

patients who were switched, we calculated the proportion who were

switched to a DOAC. Overall demographic, clinical, and practice-level

subsequently switched back to warfarin, to a different DOAC, or had

characteristics of the study population from the PINNACLE registry

all anticoagulation discontinued. The mean/median number of visits in

are shown in Table S1. The mean age of the population was 73.6

the PINNACLE dataset and the mean/median time of follow-up were

(SD 10.7) years, 57.5% were male (n = 220 097), 69.0% were white

also obtained. Additionally, patterns were determined after stratifying

(n = 264 088), and 3.2% (n = 12 283) were black or African American.

patients based on CHA2DS2-VASc score (groups: score 0-1, score 2-3,

Chronic kidney disease (CKD) was seen in 2.2% (n = 8467). Among

and score 4 or more). For the population of patients who were

patients in this analysis, 0.8% (n = 2136) had a glomerular filtration

switched, demographic, clinical, laboratory, and medication informa-

rate (GFR) 12-29 mL/min and 0.1% (n = 548) a GFR < 15 mL/min. The

tion was compared across groups.

median CHA2DS2-VASc score was 4.0 (IQR 3.0-5.0) and HAS-BLED

Categorical variables are reported as numbers (percentages) and

score was 2.0 (IQR 2.0-3.0). Practices were geographically distributed

continuous variables are reported as medians (25th and 75th percen-

across the country, with 52.1% in the Southern region and 38.1% in

tiles) or means (SD). The significance of observed differences was

urban locations.

tested using a Wilcoxon rank sum test or t-test for continuous variables and chi-square test for categorical variables. To identify significant predictors of switching, a multivariate model was created,

3.2

Switching from warfarin to DOAC

|

including all variables with P < .1 in bivariate testing.
The multivariate analyses of clinical variables were modeled in dif-

Of the 383 008 patients with AF on warfarin, 16.3% (n = 62 620)

ferent ways: (a) each component of the CHA2DS2-VASc individually,

were switched to a DOAC, while 68.8% (n = 263 609) were contin-

(b) CH2ADS2-VASc modeled per 1-point increase along with nonco-

ued on warfarin and 14.8% (n = 56 779) had anticoagulation discon-

mponent of the CHA2DS2-VASc covariates, (c) CHA2DS2-VASc

tinued (Figure 1). Among those who were switched to DOACs,

modeled as 2-6 vs 0 or 1 without HAS-BLED score, and (d) including

37.6%

(n

=

23 518)

were

switched

to

dabigatran,

37.0%

both CHA2DS2-VASc scores and HAS-BLED scores modeled per

(n = 23 195) to rivaroxaban, 24.4% (n = 15 295) to apixaban, and

1-point increase. Since there are co-linear variables in the risk scores,

1.0% (n = 612) to edoxaban. The median (25th and 75th percentiles)

the CHA2DS2-VASc score was modeled both with and without the

number of visits from the baseline visit to switching to DOAC was

HAS-BLED score. Practice-level analyses were conducted by aggre-

3.0 (2–5) with mean value of 4.2 (SD 3.6) visits. The median (25th

gating patients initially managed with warfarin at the practice-level.

and 75th percentile) duration from the baseline visit to switching to

The distribution of the proportion of patients receiving warfarin who

DOAC was 336.0 (118-767) days with mean duration of 517.0

were switched to a DOAC was determined across practices. After the

(SD 530.2) days.
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FIGURE 1

Study population

Patterns of switching stratified by CHA2DS2-VASc score tertiles are

3.3

|

Predictors of switching

shown in Figure S1. Among patients with a CHA2DS2-VASc score of 0-1
(n = 34 163), 20.7% (n = 7083) were switched to DOAC, 58.8%

Baseline demographic, clinical, and practice characteristics of the

(n = 20 077) were continued on warfarin, and 20.5% (n = 7003) had anti-

overall population with AF treated with warfarin (Table S1), patients

coagulation discontinued. For patients with a CHA2DS2-VASc score of

who were and were not switched (Table S2), and within specific medi-

2-3 (n = 144 761), 17.1% (n = 24 769) were switched to DOAC, 68.4%

cation groups (Table S3) are shown. Patients switched from warfarin

(n = 99 064) were continued on warfarin, and 14.5% (n = 20 928) had

to DOACs tended to be younger, diabetic, have private insurance, and

anticoagulation discontinued. Among patients with a CHA2DS2-VASc

a history of prior stroke; while those who were not switched tended

score of 4 or more (n = 204 084), 15.1% (n = 30 768) were switched to

to have coronary artery disease and heart failure (all P < .001). The

DOAC, 70.8% (n = 144 468) were continued on warfarin, and 14.1%

mean CHA2DS2-VASc score for those switched was 3.5 (SD 1.7) and

(n = 28 848) had anticoagulation discontinued. Switching among

for those not switched 3.7 (SD 1.6); the mean HAS-BLED score for

patients with a GFR 15-29 mL/min was 12.3% (n = 262) and among

those switched was 2.2 (SD 1.0) and for those not switched was 2.2

patients with a GFR < 15 mL/min was 6.4% (n = 35).

(SD 0.9, all P ≤ .005).
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3.4 | Multivariate models for predictors of
switching to a DOAC

regression model comparing CHA2DS2-VASc scores to scores of 0-1
showed that the odds of switching decreased as the CHA2DS2-VASc
score increased when modeled both with and without the HAS-BLED

A multivariate hierarchal regression model with the CHA2DS2-VASc

score (Figures 2b and S2). Patients with higher HAS-BLED scores, per

score and noncomponent covariates (Figure 2a) showed that

1-point increase, showed more propensity to switch (OR, 1.12; 95%CI

switching to DOACs was significantly more likely among patients of

1.10-1.13).

white race (OR, 1.22; 95%CI, 1.14-1.30), with private insurance (OR,

The findings were similar when the multivariate hierarchal

1.10; 95%CI, 1.06-1.14), and those cared for by an electrophysiologist

regression model included clinical covariates of the CHA2DS2-VASc

(OR, 1.18; 95%CI, 1.10-1.27). Switching was significantly less likely

score (Figure S3). Specifically, switching to DOACs was more likely

per 1-point increase in CHA2DS2-VASc (OR, 0.92; 95%CI, 0.91, 0.93)

with white race vs non-white (OR, 1.38; 95%CI, 1.29-1.47), private

and at practices in the Midwest as compared with the Northeast

insurance vs other (OR, 1.08; 95%CI, 1.04-1.12), prior stroke/tran-

region (OR, 0.47; 95%CI, 0.32-0.69). A multivariate hierarchical

sient ischemic attack (TIA) (OR, 1.05; 95%CI, 1.01-1.10), and

(A)

(B)
F I G U R E 2 Multivariate hierarchical
regression model with, A, CHA2DS2VASc and noncomponent covariates; B,
CHA2DS2-VASc and HAS-BLED scores
(CHA2DS2-VASc scores are compared to
reference score of 0 or 1). Variables with
nonsignificant associations included
History of Stable Angina (OR 1.05, 95%
CI 0.99-1.11), Ethnicity: Hispanic or
Latino (vs Not) (OR 1.03 95%CI
0.89-1.19), Current or Former Smoker
(vs Never Smoker) (OR 1.01 95%CI
0.98-1.04), Other (vs Nurse Practitioner)
(OR 1.00 95%CI 0.84-1.19), Physician
Provider (vs Nurse Practitioner)
(OR 1.00 95%CI 0.91-1.10), South
Region (vs Northeast) (OR 0.72 95%CI
0.48-1.10), and West Region
(vs Northeast) (OR 0.91 95%CI
0.65-1.28)
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electrophysiologists

vs

nonelectrophysiologist

cardiologist

(OR,

3.6

|

Practice variation in switching

1.16; 95%CI, 1.08-1.24). Switching was less likely with age per
10-year increase (OR, 0.82; 95%CI, 0.81-0.83), sex: male vs female

There was substantial variation in switching patterns at the practice-

(OR, 0.92; 95% CI, 0.90-0.95), history of heart failure (OR, 0.85;

level (MOR, 2.31; 95%CI, 2.11-2.56) and for providers within the

95%CI,

95%CI,

same practice (MOR, 1.46; 95%CI, 1.43-1.49). A graphical representa-

0.94-1.00), and Midwest vs Northeast Region (OR, 0.47; 95%CI,

tion of practice variation in switching to DOACs among 355 practices

0.32-0.68).

(each practice is represented by a number on the x-axis, arranged with

0.82-0.88),

history

of

diabetes

(OR,

0.97;

increasing numbers representing a larger proportion of patients
switched in that practice) is shown in Figure 4.

3.5

|

Multiple switching

The 355 practices were divided into tertiles (arranged from lowest switching rates to highest) based on the proportion of individuals

Among the 62 620 patients switched to a DOAC, 4.7% (n = 2960)

switched from warfarin to DOACs (Table S4), with tertile 1 comprised

were switched back to warfarin, 7.5% (n = 4692) were switched to

practices with the lowest switching rates. Practices with higher

another type of DOAC, and 4.6% (n = 2880) eventually discontinued

switching rates tended to have higher clinical volume, more electro-

all forms of anticoagulation (Figure S4). A visual representation of

physiologists, and were more likely to be located in the West region.

multiple changes in anticoagulation is shown in a flow cart with the

Tertile 1 was comprised of 36.8% urban locations with mean

width of each connection proportional to the number of patients

(SD) visits per year of 11 562 (SD 18 619), 84.9% physician providers,

switched (ie, a Sankey diagram; Figure 3).

and 5.9% electrophysiologists. Tertile 2 was comprised 45.0% urban

FIGURE 3

Sankey diagram of multiple anticoagulant switching
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F I G U R E 4 Practice variation for
patients switched to DOAC. *Proportion
of patients switched at each of the
355 participating centers

locations, mean (SD) visits per year of 18 259 (SD 17 351), 83.2%

The updated ACC/AHA/HRS guidelines recommend DOAC ther-

physician providers, and 8.2% electrophysiologists. Tertile 3 was com-

apy over warfarin given data demonstrating comparable efficacy with

prised 33.9% urban locations, mean (SD) visits per year 22 253

less bleeding. A meta-analysis of randomized controlled trials demon-

(SD

strated that DOACs provide significant reduction in stroke, intracra-

27 024),

84.5%

physician

providers,

and

9.6%

electrophysiologists.

nial hemorrhage, and mortality with similar major bleeding compared
to warfarin.13 Against this backdrop, previous analyses from the PINNACLE registry have shown higher rates of DOAC initiation in AF

3.7

|

Timing of switching

than the switching we observed, with approximately 60% of individuals newly initiated on anticoagulation receiving a DOAC.5-9

As time progressed, the proportion of individuals switched from war-

Potential explanations for the relatively low rate of switching

farin to DOACs increased (Table S5). Among patients switched, 13.8%

include therapeutic inertia, where providers may not choose to make

(n = 8639) were switched from May 2010 to December 2011, 34.2%

a change to anticoagulation therapy if a patient has been stable on

(n = 62 620) from January 2012 to December 2013, and 52.0%

warfarin without adverse events. Additionally, when DOACs were

(n = 32 566) from January 2014 to April 2016. Choice of agent varied,

new, some providers may have waited for accumulating evidence of

with the majority of patients who were switched early receiving

safety and benefit prior to changing therapy. This may explain why

dabigatran, but rivaroxaban and apixaban became the predominant

more switching occurred later in the study. Providers may have also

agents for later time periods in the analysis. The majority of switches

chosen to not switch patients they believed had adequate Time in

occurred more than 1 year after the index visit (Table S6), with 47.2%

Therapeutic Range (TTR) on warfarin. European guidelines suggest

(n = 29 560) >365 days after the first visit.

that providers can consider continuing warfarin if patients are able to
maintain a TTR on warfarin ≥70% of the time.14,15 However, studies
suggest that less than 50% of patients on warfarin are able to main-

4

|

DISCUSSION

tain a TTR ≥70% at 6 months and a smaller proportion of these
patients are able to maintain a TTR ≥70% at 12 months.16 Finally, cost

This analysis from a large, national outpatient registry demonstrates

is a significant barrier to DOAC use for many patients in the United

that approximately 1 in 6 AF patients treated with warfarin, who were

States, but is less of an issue in Europe where there is widespread pre-

eligible to be switched to a DOAC, were switched between October

scription drug coverage. This is further emphasized by a study from a

1, 2010 and May 1, 2016. There were significant differences in

Danish cohort that showed significantly higher rates of switching than

switching based on clinical/sociodemographic factors, and substantial

we observed in our analysis.17

variation in care patterns across practices. This relatively low rate of

Broadly speaking, the substantial practice level variation suggests

switching represents an important target for improvement as DOACs

that there are multiple mechanisms underlying these findings. Both at

have been established as first line therapy for most patients with non-

the practice level and among providers within the same practice, there

valvular AF.4

was substantial variation in switching patterns, emphasizing a lack of a
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unified approach to switching patients from warfarin to DOACs.

The relatively low rate of switching and the potential differences

With some practices switching approximately 65% of patients, while

observed in the PINNACLE registry may serve as an important perfor-

others did not switch any, this highlights the need for additional

mance

performance improvement efforts to better align care with practice

AF. Switching patients from warfarin to DOACs is especially impor-

guidelines.

tant given the 2019 update to the ACC/AHA/HRS AF guidelines,

improvement

target

for

treatment

of

patients

with

Another key finding from our analysis is that switching was less

which favor DOACs over warfarin for stroke prevention with a class

prevalent among patients with increasing age, non-white race, those

1A recommendation.4 Increased cost and other barriers to switching

without private insurance, and men. There have been numerous dis-

must be addressed, including patient perspectives and preferences.

parities in many aspects of AF management, including initiation of

The large degree of practice variation seen in this study highlights the

DOACs and ablation.5-9 Although predictors of switching have not

lack of a standardized approach for switching patients.

been extensively examined in the literature, disparities in DOAC initiation have been observed based on age, race, insurance status, geographic region, female sex, lower household income, higher stroke

4.1

|

Limitations

risk, and higher bleeding risk.18-19 In a Danish study that specifically
focused on switching from warfarin to DOACs, it was similarly

There were a few important limitations of this analysis. First, since the

observed that younger age, female sex, history of stroke, and history

PINNACLE registry contains data abstracted from practices participat-

of bleeding were predictors of switching.17 Our analysis adds to this

ing in a quality improvement registry, it is possible that the data may

literature and further heightens the need for quality improvement

not be representative of other practices in the United States. This pro-

efforts to address and close these disparities.

gram provides additional support to facilitate guideline recommended

It is also notable that switching was more prevalent with

treatments that may not be available in most practices. Information

increased bleeding risk (based on HAS-BLED scores) but less preva-

such as accessibility to INR testing (ie, patients living far away from

lent with increased stroke risk (based on CHA2DS2-VASc scores). We

testing centers), household income, and drug benefit plans would be

know from other studies that bleeding avoidance is an important

helpful to better define the role of cost in limiting switching. Addition-

driver of decision-making20 and represents an important assessment

ally, as with any clinical management decision, there are often relevant

and reassessment of anticoagulation choices. Providers may have

factors that fall outside of information that can be collected in a regis-

been cautious to switch patients at higher risk of stroke because war-

try, such as patient preference and unmeasured practice variation.

farin was the established agent and because of the inertia to change

Other factors such as nonadherence, or TTR with warfarin may have

in the absence of a specific clinical issue. Conversely, the ability to

affected anticoagulation patterns and switching to DOACs, but were

lower bleeding risk with a specific therapeutic intervention may repre-

not collected in the PINNACLE registry. Another limitation is the rela-

sent a key element in decision-making. The higher likelihood of

tively sparse data on renal function available for our analysis. Renal

switching per 1-point increase in HAS-BLED may be related to the

dysfunction is an important consideration in choosing anticoagulation

lower bleeding risk of DOAC therapy compared to warfarin.21-23

for AF patients and previously was a limitation for DOAC use,

The lower likelihood of switching among individuals per 1-point

although current guidelines now suggest it is reasonable to ant-

increase in the CHA2DS2-VASc score differs from previous registry

icoagulate these patients with apixaban.4 With a relatively low pro-

data on DOAC initiation. Numerous studies have shown that DOAC

portion of patients with CKD, we were not able to systematically

initiation was less likely with both increasing stroke and bleeding

examine the association of renal function on switching.

risk.6,7,14 This was believed to be related to the lack of commercially
available bleeding reversal agents and commonalities among components of the CHA2DS2-VASc and HAS-BLED scores, meaning a higher

5

|
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stroke risk correlates with a higher bleeding risk. Although reversal
agents for DOACs are now available, these were not in wide use dur-

In a contemporary cohort of patients with AF treated with warfarin,

ing the majority of our analysis. As DOAC reversal agents become

switching from warfarin to DOACs was relatively uncommon.

more widely available, providers may be more likely to switch patients

Switching was less likely with rising stroke risk, but more likely with

in the future.

higher bleeding risk. Additionally, there was significant practice varia-

Another significant predictor of switching was treatment by an

tion in switching. In the context of the 2019 update to the ACC/AHA/

electrophysiologist. This observation may reflect either lack of com-

HRS guidelines, which favor DOACs over warfarin, these findings may

fort with these newer agents or decreased awareness of potential

help benchmark performance and identify areas of improvement.

benefits among nonsubspecialty practitioners. As a result, referrals to
electrophysiologists would impact which patients would be switched.

ACKNOWLEDG MENTS

Lower rates of referrals to specialists have been reported in patients

Dr Christopher T. Sciria, MD and Dr Nihar Desai had full access to all

24

post-MI among different racial and lower socioeconomic groups,

the data in the study and take responsibility for the integrity of the

and if such disparities are also present among patients with AF, this

data and the accuracy of the data analysis. The Baim Institute con-

would in turn affect switching to DOACs.

ducted and is responsible for the data analysis. T. M. M.: Washington

751

SCIRIA ET AL.

University

School

of

Medicine

(employment);

NIH

NCATS

1U24TR002306-01 (grant funding); Creative Educational Concepts
(consultant). A. O.; Y. L., Y. S., Y. Z., J. J. L.: None. S. S. V.: Department

10.

of Veterans Affairs Health Services Research and Development;
World Heart Federation, Freeman: NHLBI: K23 HL118147-01;
R56HL142765; R01HL142765; American College of Cardiology
National Cardiovascular Data Registry.
CONF LICT OF IN TE RE ST

11.

12.

The authors declare no potential conflict of interests.
AUTHOR CONTRIBUTIONS

13.

Salim S. Virani: American College of Cardiology (Associate Editor for
Innovations, acc.org). James V. Freeman: Research Support: ACC
NCDR; Modest consulting/advisory board: Medtronic, Boston Scien-

14.

tific, Biosense Webster, Janssen Pharmaceuticals. Nihar R. Desai:
Research Support: Centers for Medicare and Medicaid Services; Con-

15.

sulting/advisory board: Amgen, Astra Zeneca, Boehringer Ingelheim,
Relypsa. All other authors have no disclosures at this time.

16.

ORCID

17.

Christopher T. Sciria
Salim S. Virani

https://orcid.org/0000-0002-0730-7799

https://orcid.org/0000-0001-9541-6954

Christopher Cannon

https://orcid.org/0000-0003-4596-2791

RE FE R ENC E S
1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke
statistics–2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322.
2. Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative
effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity
weighted nationwide cohort study. BMJ. 2016;353:i3189.
3. López-López JA, Sterne JA, Thom HH, et al. Oral anticoagulants for
prevention of stroke in atrial fibrillation: systematic review, network
meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.
4. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused
update of the 2014 AHA/ACC/HRS guideline for the Management of
Patients with Atrial Fibrillation: a report of the American College of
Cardiology/American Heart Association task force on clinical practice
guidelines and the Heart Rhythm Society. Circulation. 2019;140:
e125-e151.
5. Hsu JC, Chan PS, Tang F, Maddox TM, Marcus GM. Oral anticoagulant prescription in atrial fibrillation patients with a low risk of thromboembolism: insights from the NCDR PINNACLE registry. JAMA
Intern Med. 2015;175(6):1062-1065.
6. Hsu JC, Chan PS, Tang F, et al. Differences in anticoagulant therapy
prescription in patients with paroxysmal versus persistent atrial fibrillation: insights from the NCDR PINNACLE registry. Am J Med. 2015;
128(6):654.e1-654.e10.
7. Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy
prescription in patients with atrial fibrillation across the spectrum of
stroke risk: insights from the NCDR PINNACLE registry. JAMA Cardiol. 2016;1(1):55-62.
8. Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll
Cardiol. 2017;69(20):2475-2484.
9. Thompson LE, Maddox TM, Lei L, et al. Sex differences in the use of
Oral anticoagulants for atrial fibrillation: a report from the National

18.

19.

20.

21.

22.

23.
24.

Cardiovascular Data Registry (NCDR®) PINNACLE registry. J Am
Heart Assoc. 2017;6(7):e005801.
Chan PS, Oetgen WJ, Buchanan D, et al. Cardiac performance measure compliance in outpatients: the American College of Cardiology
and National Cardiovascular Data Registry's PINNACLE (Practice
Innovation and Clinical Excellence) program. J Am Coll Cardiol. 2010;
56(1):8-14.
Messenger JC, Ho KK, Young CH, et al. The National Cardiovascular
Data Registry (NCDR) data quality brief: the NCDR data quality program in 2012. J Am Coll Cardiol. 2012;60(16):1484-1488.
Larsen K, Merlo J. Appropriate assessment of neighborhood effects
on individual health: integrating random and fixed effects in multilevel
logistic regression. Am J Epidemiol. 2005;161(1):81-88.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy
and safety of new oral anticoagulants with warfarin in patients with
atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;
383(9921):955-962.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the
management of atrial fibrillation developed in collaboration with
EACTS. Eur Heart J. 2016;37(38):2893-2962.
Senoo K, Lau YC, Lip GY. Updated NICE guideline: management of
atrial fibrillation. Expert Rev Cardiovasc Ther. 2014;12:1037-1040.
Bonde AN, Staerk L, Lee CJ, et al. Outcomes among patients with
atrial fibrillation and appropriate anticoagulation control. J Am Coll
Cardiol. 2018;72(12):1357-1365.
Fosbøl EL, Vinding NE, Lamberts M, et al. Shifting to a non-vitamin K
antagonist oral anticoagulation agent from vitamin K antagonist in
atrial fibrillation. EP Europace. 2017;20(6):e78-e86.
Rodwin BA, Salami JA, Spatz ES, et al. Variation in the use of warfarin
and direct oral anticoagulants in atrial fibrillation and associated cost
implications. Am J Med. 2018;132(1):61-70.
Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of
oral anticoagulants in patients with atrial fibrillation—quality and cost
implications. Am J Med. 2014;127(11):1075-1082.
Desai NR, Peterson ED, Chen AY, et al. Balancing the risk of mortality
and major bleeding in the treatment of NSTEMI patients—a report
from the National Cardiovascular Data Registry. Am Heart J. 2013;
166(6):1043-1049.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin
in patients with atrial fibrillation. N Engl J Med. 2009;361(12):11391151.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):
981-992.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in
nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
Desai NR, Udell JA, Wang Y, et al. Trends in performance and opportunities for improvement on a composite measure of acute myocardial infarction care: findings from the National Cardiovascular Data
Registry. Circ Cardiovasc Qual Outcome. 2019;12(3):e004983.

SUPPORTING INF ORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.

How to cite this article: Sciria CT, Maddox TM, Marzec L,
et al. Switching warfarin to direct oral anticoagulants in atrial
fibrillation: Insights from the NCDR PINNACLE registry. Clin
Cardiol. 2020;43:743–751. https://doi.org/10.1002/clc.23376

